[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370728-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370728-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","towards-the-development-of-next-generation-lung-cancer-immunotherapy","Towards the development of next-generation lung cancer immunotherapy","","The immune system eliminates pathogens and viruses, and can also recognize and suppress cancer when normal cells become malignant. Cancer cells acquire traits that influence immune regulation, enabling suppression of antitumor immunity and escape from immune attack. Treatments therefore aim to remove cancer-mediated immune suppression and restore the immune system’s capacity to eliminate tumors. Immunotherapies include immune checkpoint inhibitors, cytokines, cancer vaccines, and effector cell therapies such as CD8+ T cells and NK cells, supported by understanding immunity-related cells, molecules, and the local tumor microenvironment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/towards-the-development-of-next-generation-lung-cancer-immunotherapy/370728/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/towards-the-development-of-next-generation-lung-cancer-immunotherapy/370728.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why can the immune system fail to control cancer in the tumor microenvironment?","Question",{"text":63,"@type":64},"Cancer cells can suppress antitumor immune regulation within the tumor microenvironment, weakening immune activity and enabling immune escape.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What major immunotherapy categories are described for next-generation lung cancer treatment?",{"text":68,"@type":64},"The text covers immune checkpoint inhibitors, cytokine therapy, cancer vaccines, and effector cell therapies using immune cells such as CD8+ T cells and NK cells.",{"name":70,"@type":61,"acceptedAnswer":71},"How does cytokine therapy described in the abstract work?",{"text":72,"@type":64},"Cytokine therapy activates the immune system by injecting substances produced by immune cells (e.g., interleukin 2 and interferon alpha) to increase the immune system’s ability to attack cancer cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370728,1790380927,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Towards the development of next-generation lung cancer immunotherapy  \nYoshinobu Ichiki1, Nako Saito1, Ryo Taguchi1, Tetsuya Umesaki1, Hiroyuki Nitanda1, Hirozo Sakaguchi1, Hironori Ishida1, Tomonori Kawasaki2, Hisao Imai3, Kyoichi Kaira3, Hiroshi Kagamu3  \n1Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan; 2Department of Diagnostic Pathology, Saitama Medical University International Medical Center, Saitama, Japan; 3Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan  \nContributions: (I) Conception and design: Y Ichiki; (II) Administrative support: Y Ichiki; (III) Provision of study materials or patients: N Saito, R Taguchi, T Umesaki; (IV) Collection and assembly of data: Y Ichiki, H Nitanda; (V) Data analysis and interpretation: H Sakaguchi, H Ishida, T Kawasaki, H Imai, K Kaira, H Kagamu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \nCorrespondence to: Yoshinobu Ichiki, MD, PhD. Department of General Thoracic Surgery, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, [Japan. Email: y-ichiki@med.uoeh-u.ac.jp](Japan. Email: y-ichiki@med.uoeh-u.ac.jp).  \nAbstract: The immune system attempts to eliminate foreign substances, such as pathogens and viruses, that invade the body. As normal cells transform into cancerous cells, the immune system can eliminate these cells and suppress cancer onset. The immune system is regulated so that it does not become overactive or attack normal cells. When cancer cells transform from normal cells, they acquire various characteristics, and some cancer cells influence the regulatory function of the immune system to suppress it and escape immune attack. Therefore, treatments have been developed to eliminate the suppression of the immune system by cancer cells and to restore the immune system’s ability to eliminate cancer cells. Immunotherapies include immune checkpoint inhibitors, cytokines, cancer vaccines, and effector cell therapies. Cytokine therapy activates the immune system by injecting substances produced by immune cells (such as interleukin 2 and interferon alpha) into the body, thereby increasing the ability of the immune system to attack cancer cells.  \nCancer vaccine therapy enhances the attack on cancer cells by injecting substances (antigens) that serve as markers for cancer cells into the body to make it easier for immune cells to detect the cancer. Depending on the type of antigen, cancer peptides, tumor cells, and dendritic cell vaccines are available. Effector cell therapy is a treatment method in which immune cells that directly attack cancer cells [CD8+ T cells, natural killer (NK) cells, etc.] are taken from the patient’s body, expanded outside the body, activated, and returned to the body to attack cancer cells. To develop these treatments, it is essential to understand the cells and molecules related to immunity as well as the local tumor environment. In this article, we consider the factors  \nrelated to antitumor immunity.  \nKeywords: Lung cancer; immune check inhibitor (ICI); cancer immunology; cytotoxic T lymphocyte (CTL)  \nSubmitted Nov 17, 2024. Accepted for publication Apr 09, 2025. Published online Jun 25, 2025.  \ndoi: 10.21037/tlcr-2024-1097  \nView this article at: [https://dx.doi.org/10.21037/tlcr-2024-1097](https://dx.doi.org/10.21037/tlcr-2024-1097)  \nIntroduction  \nTherapies for lung cancer have undergone dramatic changes, with immune checkpoint inhibitors (ICIs) playing key roles. The antitumor immune response that acts locally in the area of the tumor is primed in the regional lymph nodes. However, it is also recognized that there are mechanisms  \nthat can maintain the activity of antitumor cells in the locality of the cancer. Examination of the immune tumor microenvironment (TME) has critical prognostic value and can supplement histopathological and mole","cbCainYJIvAHZAHn","https://ap.wps.com/l/cbCainYJIvAHZAHn","pdf",371861,15,"English","# Introduction\n## Immune checkpoint inhibitors and local antitumor immunity\n## Immune tumor microenvironment (TME) and prognostic value\n## Adaptive and innate immunity in tumor control","[{\"question\":\"Why can the immune system fail to control cancer in the tumor microenvironment?\",\"answer\":\"Cancer cells can suppress antitumor immune regulation within the tumor microenvironment, weakening immune activity and enabling immune escape.\"},{\"question\":\"What major immunotherapy categories are described for next-generation lung cancer treatment?\",\"answer\":\"The text covers immune checkpoint inhibitors, cytokine therapy, cancer vaccines, and effector cell therapies using immune cells such as CD8+ T cells and NK cells.\"},{\"question\":\"How does cytokine therapy described in the abstract work?\",\"answer\":\"Cytokine therapy activates the immune system by injecting substances produced by immune cells (e.g., interleukin 2 and interferon alpha) to increase the immune system’s ability to attack cancer cells.\"}]","Towards the development of next-generation lung cancer immunotherapy | PDF",1790190088,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dd116a5e5b3f7cec4d2d8d17b50c96b.webp",983,1287,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbb0c67957cf1ec72727990d1f18c74f.webp",982,1286,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ec025b600dc73e3bc2ee274c8ebaf88.webp",981,1284,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/270e0c99fda83e5eace95d054d99eefd.webp",980,1283]